Effect of SHR8058 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction

Inclusion Criteria: 1. Signed ICF (Informed Consent Form) 2. Subject-reported history of Drye Eye Disease (DED) in both eyes 3. Ability and willingness to follow instructions, including participation in all study assessments and visits Exclusion Criteria: 1. clinically significant slit lamp findings or abnormal lid anatomy at screening, including eye trauma, pterygium, active blepharitis, and active lid margin inflammation; 2. Stevens-Johnson syndrome or other severe systemic autoimmune diseases; 3. underwent LipiFlow procedure or intention pulsed light therapy within 6 months before baseline, or received Meibomian gland massage treatment within 2 weeks before baseline; 4. received or removed permanent lacrimal plug within 3 months before baseline; 5. DED secondary to scarring, radiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells; 6. ocular or periocular malignancy; 7. active ocular allergies, or allergy to the study drug or its components; 8. ongoing ocular or systemic infection; 9. use of contact lenses within 1 month before screening; 10. intraocular surgery or ocular laser surgery within 6 months before enrollment; 11. uncontrolled systemic disease or history of herpetic keratitis; 12. use of topical steroids, topical cyclosporine, lifitegrast, serum tears, or topical anti-glaucoma medication within 60 days before screening; 13. used any known oral drugs that could have caused eye dryness within 1 month before screening; 14. participated in or were participating in other clinical trials drugs or device within 60 days before baseline; 15. inappropriate to participate for other reasons judged by the investigators.